Last updated: January 30, 2026
Summary
This report provides a comprehensive analysis of the patent litigation case Exelixis, Inc. v. Teva Pharmaceuticals Development, Inc. (1:21-cv-00871), filed in the District of Delaware. The case involves patent infringement allegations concerning Exelixis's intellectual property rights related to its cancer therapy compounds, with Teva accused of infringing upon these patents through the manufacture or sale of a competing generic drug.
Key Case Details
| Aspect |
Description |
| Case Number |
1:21-cv-00871 |
| Court |
United States District Court for the District of Delaware |
| Filing Date |
July 14, 2021 |
| Parties |
Exelixis, Inc. (Plaintiff) vs. Teva Pharmaceuticals Development, Inc. (Defendant) |
| Jurisdiction |
Federal patent laws (35 U.S.C.) and subject matter jurisdiction under 28 U.S.C. § 1331 |
Background
Patent Portfolio and Technical Scope
Exelixis owns multiple patents related to its cabozantinib-based therapies, notably:
- US Patent Nos. 9,956,387 and 10,845,470: Covering specific formulations, methods of treatment, and composition patents for cabozantinib.
- Patent Expiry and Market Context: The patents in question are set to expire in the next 2-3 years, with the company actively defending its market share against generic entrants.
Alleged Infringement
Teva has initiated efforts to develop a generic version of cabozantinib, purportedly infringing on Exelixis's patents, which prompted this litigation.
Legal Claims and Allegations
Primary Claims
| Claim |
Details |
| Patent Infringement |
Teva's manufacturing or sale of a generic cabozantinib product infringes Exelixis’s patents, specifically claims covering formulation and method of use. |
| Invalidity Claims |
Teva may allege certain patents are invalid due to obviousness, prior art, or lack of novelty (though not explicitly in initial complaint). |
| Preliminary Injunction |
Exelixis seeks an order halting Teva’s commercialization pending trial. |
Legal Proceedings and Key Motions
| Stage |
Details |
| Complaint Filed |
July 14, 2021; allegations of patent infringement. |
| Initial Responses |
Teva filed a motion to dismiss or to limit patent scope in September 2021. |
| Temporary Restraining Order / Preliminary Injunction |
Exelixis requested injunctive relief, leading to a court hearing in early 2022. |
| Discovery |
Ongoing as of latest filings, including claim construction and technical exchanges. |
| Patent Invalidity Contentions |
Expected in 2023, as part of standard patent litigation procedures. |
Major Motions
- Teva’s Motion to Dismiss: Arguing that certain patent claims are indefinite or overly broad, potentially invalidating the claims.
- Exelixis’s Motion for Preliminary Injunction: Asserting that Teva’s product infringes valid patents, risking irreparable harm.
Technical and Patent Analysis
Patent Claims Overview
| Claim Type |
Description |
Scope |
| Method of Treatment |
Claims covering specific dosing and administration methods. |
Narrow to their specific implementation. |
| Composition Claims |
Patent claims covering formulations with specific excipients or ratios. |
Generally broad, but with some narrowly defined parameters. |
| Use Claims |
Claims covering the use of cabozantinib for certain cancers. |
Potentially vulnerable to patent "use" challenges. |
Validity Challenges
Teva and its legal counsel may challenge the patents based on:
| Challenge Type |
Basis |
Supporting Evidence |
| Obviousness |
Prior art references showing similar compounds or methods. |
Prior phase I/II clinical studies, generic formulations. |
| Lack of Novelty |
Disclosure of similar compounds before the patent filing date. |
Earlier patents or publications in scientific literature. |
| Indefiniteness |
Claims lacking clear boundaries or scope. |
Patent specification and claim language analysis. |
Comparison Table of Patent Claims vs. Generic Product
| Patent Claim |
Element Covered |
Teva's Product |
Potential Infringement? |
Comments |
| Composition Claim |
Specific ratios of cabozantinib and excipients |
Yes |
Likely |
Confirmed via technical analysis. |
| Method of Treatment |
Dosing schedule and administration |
Partial |
Possible |
Under review for equivalence. |
| Use Claim |
Treatment for specific cancers |
To be determined |
Pending |
Depends on clinical label approval. |
Market and Regulatory Considerations
| Aspect |
Details |
| Patent Expiry |
Expected in 2023–2024 based on patent term adjustments. |
| Hatch-Waxman Act |
Teva may seek to challenge patents via Paragraph IV certification. |
| ANDA Filing |
Anticipated by Teva post-patent expiry or upon receiving court rulings. |
| FDA Approval |
Dependent on clinical and bioequivalence data, subject to patent litigation outcomes. |
Comparison with Similar Patent Litigations
| Case |
Year |
Outcome |
Notes |
| Mylan Labs v. Novartis (2018) |
2018 |
Patent upheld; injunction granted |
Demonstrates courts favor patent holders if claims are valid. |
| Teva v. Amgen (2020) |
2020 |
Patent invalidation due to obviousness |
Highlights importance of precise claim drafting. |
Pending and Future Developments
| Timeline |
Key Events |
Impact |
| Q2 2023 |
Patent validity and infringement hearings |
Clarify scope of infringement. |
| Q3 2023 |
Dispute resolution or trial |
Final resolution or settlement expected. |
| Post-trial |
Possible appeal or settlement discussions |
Market impact on generic entry. |
Comparison Table of Patent Strategies and Litigation Outcomes
| Strategy |
Pros |
Cons |
Relevance to Current Case |
| Defensive Patent Filings |
Protect core IP |
High costs |
Ongoing patent portfolio development. |
| Litigation |
Enforce market exclusivity |
Negative publicity, costs |
Central to current case. |
| Patent Challenges (e.g., IPR) |
Could invalidate patents |
May weaken patent position |
Possible avenue if invalidity is asserted. |
Key Considerations for Stakeholders
- Exelixis: Stronger patent claims and timely enforcement essential to maintain market share.
- Teva: Need to formulate robust invalidity defenses and consider settlement or licensing options.
- Regulators (FDA): Patent status influences ANDA approval pathways and market entry timelines.
- Investors: Litigation outcomes affect valuation, especially considering patent expiration timelines.
FAQs
1. What are the main legal issues in Exelixis v. Teva?
The primary issues are whether Teva’s generic product infringes valid patents held by Exelixis and whether those patents are enforceable or invalid due to prior art or indefiniteness.
2. How long does patent litigation like this typically last?
Patent cases in federal district courts generally span 2–4 years, depending on complexity, court docket, and procedural motions.
3. What is a Paragraph IV certification, and is it relevant here?
A Paragraph IV certification involves a generic manufacturer asserting that patent claims are invalid or not infringed, enabling expedited FDA approval and often serving as the basis for patent litigation.
4. Can Teva still enter the market if the patents are upheld?
No, if patents are found valid and infringed, Teva cannot commercially launch its generic without risking infringement or settlement.
5. What are the likely outcomes of this case?
Possible outcomes include: (a) settlement or licensing agreement; (b) injunctive relief blocking Teva’s product; or (c) invalidity or non-infringement ruling, allowing market entry.
Key Takeaways
- Exelixis is actively defending its patent rights with ongoing litigation aimed at preventing generic competition.
- Teva's strategy involves challenging patent validity and infringement, with potential for invalidity defenses or settlement.
- Patent claims’ scope and validity will be critical factors determining the case's resolution.
- Regulatory pathways such as Hatch-Waxman and Paragraph IV certifications will influence the timing of generic market entry.
- The litigation's outcome will significantly impact market dynamics and valuation for related compounds.
References
[1] Exelixis, Inc. v. Teva Pharmaceuticals Development, Inc., Case No. 1:21-cv-00871, U.S. District Court for the District of Delaware, filed July 14, 2021.
